Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(9)
DEVICE(8)
BIOLOGICAL(7)
DRUG(1)
VGX-3100
4 trials
phase_2phase_3
inovio-pharmaceuticals
CELLECTRA™ 2000
3 trials
phase_1_2phase_2
inovio-pharmaceuticals
INO-5401
2 trials
phase_1_2
inovio-pharmaceuticals
INO-3112
2 trials
phase_1_2
inovio-pharmaceuticals
INO-9012
2 trials
phase_1_2
inovio-pharmaceuticals
CELLECTRA™-5P
2 trials
phase_1_2
inovio-pharmaceuticals
Electroporation (EP)
1 trial
phase_3
inovio-pharmaceuticals
CELLECTRA™-5PSP
1 trial
phase_3
inovio-pharmaceuticals

+8 more interventions

16 unique interventions4 categories

Analytics

Trial Phases

Phase 16
Phase 27
Phase 32

Trial Status

Completed9
Other1

Role Distribution

Other Roles10

Activity Timeline

Clinical Trials (10)

NCT04398433Phase 1/2Completed
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Respiratory Papillomatosis
StudydirectorStart date: 2020-10-07
NCT03721978Phase 3Completed
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Cervical DysplasiaCervical High Grade Squamous Intraepithelial LesionHSIL
StudydirectorStart date: 2019-02-28
NCT03502785Phase 1/2Completed
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Urothelial Carcinoma
StudydirectorStart date: 2018-07-24
NCT03491683Phase 1/2Active Not Recruiting
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Glioblastoma
StudydirectorStart date: 2018-05-31
NCT03499795Phase 2Completed
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Anal Neoplasm
StudydirectorStart date: 2018-05-15
NCT03180684Phase 2Completed
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Human Papillomavirus (HPV)Pre-cancerous Lesions of the VulvaVIN2+4 more
StudydirectorStart date: 2017-08-31
NCT03185013Phase 3Completed
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Cervical DysplasiaCervical High Grade Squamous Intraepithelial LesionHSIL
StudydirectorStart date: 2017-06-28
NCT02163057Phase 1/2Completed
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Cancer
StudydirectorStart date: 2014-08-13
NCT02172911Phase 1/2Completed
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
Cervical Cancer
StudydirectorStart date: 2014-06-06
NCT02241369Phase 1Completed
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
Aerodigestive Precancerous Lesions and Malignancies
Studydirector

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Cancer of the Uterine CervixGlioblastoma
Similarity Score4%

Michael Hudgens, PhD

University of North Carolina, Chapel Hill

Related
4 trials

Shared therapeutic areas:

Cancer of the Uterine CervixHuman Papillomavirus (HPV)
Similarity Score4%

Jun Zhang, master

Xiamen University

Related
12 trials

Shared therapeutic areas:

Cancer of the Uterine CervixUterine Cervical Dysplasia
Similarity Score4%

Lei Li, M.D.

Peking Union Medical College Hospital

Related
46 trials

Shared therapeutic areas:

Cancer of the Uterine CervixUterine Cervical Dysplasia
Similarity Score4%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Cancer of the Uterine CervixGlioblastoma
Similarity Score4%

Juntao Ran

LanZhou University

Related
1 trials

Shared therapeutic areas:

Cancer of the Uterine Cervix
Similarity Score2%

Xiaojie Ma

Affiliated Hospital of North Sichuan Medical College

Related
1 trials

Shared therapeutic areas:

Cancer of the Uterine Cervix
Similarity Score2%

Herui Yao, PhD

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Related
11 trials

Shared therapeutic areas:

Cancer of the Uterine Cervix
Similarity Score2%

Ciro Gallo, M.D., Ph.D.

University of Campania Luigi Vanvitelli

Related
8 trials

Shared therapeutic areas:

Cancer of the Uterine Cervix
Similarity Score2%

Lung-Ji Chang, PhD

Shenzhen Geno-Immune Medical Institute

Related
18 trials

Shared therapeutic areas:

Cancer of the Uterine Cervix
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (10)

Showing 10 of 10 trials

NCT04398433Phase 1/2StudyDirector

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Respiratory Papillomatosis
Completed
NCT03721978Phase 3StudyDirector

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Cervical DysplasiaCervical High Grade Squamous Intraepithelial LesionHSIL
Completed
NCT03502785Phase 1/2StudyDirector

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Urothelial Carcinoma
Completed
NCT03491683Phase 1/2StudyDirector

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Glioblastoma
Active Not Recruiting
NCT03499795Phase 2StudyDirector

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Anal Neoplasm
Completed
NCT03180684Phase 2StudyDirector

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Human Papillomavirus (HPV)Pre-cancerous Lesions of the VulvaVIN2+4 more
Completed
NCT03185013Phase 3StudyDirector

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Cervical DysplasiaCervical High Grade Squamous Intraepithelial LesionHSIL
Completed
NCT02163057Phase 1/2StudyDirector

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Cancer
Completed
NCT02172911Phase 1/2StudyDirector

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Cervical Cancer
Completed
NCT02241369Phase 1StudyDirector

Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies

Aerodigestive Precancerous Lesions and Malignancies
Completed

All 10 trials loaded